Company Monopar Therapeutics Inc.

Equities

MNPR

US61023L1089

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-01 pm EDT			5-day change	1st Jan Change
0.65 ^USD	-1.53%		-1.07%	+91.06%

Apr. 16	Monopar Therapeutics Files Provisional Patent for New MNPR-101 Construct	MT
Apr. 16	Monopar Therapeutics Inc. Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings	CI

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.

Number of employees: 10

Managers	Title	Age	Since
Chandler Robinson FOU	Founder	40	14-11-30
Kim Tsuchimoto DFI	Director of Finance/CFO	61	15-05-31
Laura Kelly CTO	Chief Tech/Sci/R&D Officer	-	21-02-17
Andrew Cittadine COO	Chief Operating Officer	52	21-05-31
Patrice Rioux CTO	Chief Tech/Sci/R&D Officer	73	16-11-30

Members of the board	Title	Age	Since
Michael Brown BRD	Director/Board Member	67	14-11-30
Arthur Klausner BRD	Director/Board Member	64	17-07-31
Kim Tsuchimoto DFI	Director of Finance/CFO	61	15-05-31
Christopher Starr FOU	Founder	71	14-11-30
Raymond Anderson BRD	Director/Board Member	82	17-03-31
Chandler Robinson FOU	Founder	40	14-11-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	17,454,925	8,316,964 ( 47.65 %)	0	47.65 %

Name	Equities	%	Valuation
Tacticgem LLC 48.21 %	7,166,667	48.21 %	5 M $
Jeffrey Klunzinger 4.660 %	692,800	4.660 %	471 797 $
Michael Brown 1.587 %	235,863	1.587 %	160 623 $
Chandler Robinson 1.117 %	166,131	1.117 %	113 135 $
Christopher Starr 0.5063 %	75,263	0.5063 %	51 254 $
Andrew Cittadine 0.3876 %	57,624	0.3876 %	39 242 $
Kim Tsuchimoto 0.3395 %	50,470	0.3395 %	34 370 $
Renaissance Technologies LLC 0.3235 %	48,086	0.3235 %	32 747 $
Vanguard Group, Inc. (Subfiler) 0.3038 %	45,167	0.3038 %	30 759 $
Geode Capital Management LLC 0.2771 %	41,199	0.2771 %	28 057 $

Monopar Therapeutics, Inc.

1000 Skokie Boulevard Suite 350

60091, Wilmette

+847 388 0349

http://www.monopartx.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.65 USD

Average target price

3.363 USD

Spread / Average Target

+417.44%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MONOPAR THERAPEUTICS INC.	+91.06%	11.35M
IQVIA HOLDINGS INC.	+0.67%	42.4B
LONZA GROUP AG	+44.30%	40.04B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+6.55%	24.94B
ALNYLAM PHARMACEUTICALS, INC.	-21.66%	18.96B
MEDPACE HOLDINGS, INC.	+29.96%	12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.57%	11.95B
UNITED THERAPEUTICS CORPORATION	+16.03%	11.32B
BIO-TECHNE CORPORATION	-4.80%	11.55B

Other Biotechnology & Medical Research